Homepage Top Section1

The approval covers patients with OSAS who continue to experience EDS while receiving treatment for airway obstruction. It also applies to narcolepsy with and without cataplexy, a condition

Insight Partners and Medical Excellence Capital led the round, with additional investment from Pfizer Ventures and M Ventures, the corporate venture capital arm of Merck KGaA, all joining

The Liverpool Accelerate Laboratory was developed with the LSTM-led iiCON: Infection Innovation Consortium and received funding from the Liverpool City Region Combined Authority. It is due to open

The 72,300ft² site is said to be the largest single-site contract development and manufacturing organisation (CDMO) facility in North America for radiopharmaceutical development to date. It supports low-to-high

The agreement gives Médunik Canada immediate responsibility for Diacomit’s sales, marketing, and medical affairs activities throughout the country. It aims to leverage Médunik Canada’s network and rare disease

This marks the first FDA-approved treatment for ET in nearly 30 years. The approval is based on data from the global Phase III SURPASS ET trial, which demonstrated

The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of 30 April 2027. Also known as bimatoprost grenod or NCX 470, K-911 is

The regimens include Ziihera combined with Tevimbra (tislelizumab-jsgr) and fluoropyrimidine- and platinum-containing chemotherapy for patients with HER2+ immunohistochemistry (IHC) 3+ or IHC 2+/in situ hybridisation (ISH)+. The other

This regulatory status is designed for therapies targeting rare, life-threatening, or chronically debilitating diseases. Cushing’s syndrome of endogenous origin is a rare endocrine disease caused in most instances